XML 45 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Summary of Significant Accounting Policies - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended 23 Months Ended
Dec. 30, 2017
USD ($)
Sep. 28, 2018
USD ($)
Mar. 30, 2018
USD ($)
Sep. 29, 2017
USD ($)
Sep. 28, 2018
USD ($)
segment
product
Sep. 29, 2017
USD ($)
Dec. 28, 2018
USD ($)
Dec. 29, 2017
USD ($)
Organization And Summary Of Significant Policies [Line Items]                
Number of products that entered in the commercial marketplace | product         3      
Number of business segments | segment         1      
Increase in net cash provided by investing activities         $ (155,051) $ 55,128    
Reduction to accumulated deficit $ (1,570,434) $ (1,240,452)     (1,240,452)     $ (1,829,172) [1]
Revenues   225,397   $ 152,510 $ 625,224 332,405    
Prompt payment discount rate         2.00%      
Percent of total available discounts expected to be earned         100.00%      
Products Derived from Cabozantinib                
Organization And Summary Of Significant Policies [Line Items]                
Number of products that entered in the commercial marketplace | product         2      
Licenses                
Organization And Summary Of Significant Policies [Line Items]                
Revenues   51,323   54,335 $ 152,261 74,706    
Collaborative Arrangement with Ipsen                
Organization And Summary Of Significant Policies [Line Items]                
Milestone payments earned               $ 125,000
Revenues   57,186   $ 50,679 145,038 60,703    
Collaborative Arrangement with Ipsen | EMA Approval - RCC                
Organization And Summary Of Significant Policies [Line Items]                
Revenues   36,900     36,900      
Collaborative Arrangement with Ipsen | EMA Approval - RCC | Licenses                
Organization And Summary Of Significant Policies [Line Items]                
Revenues   200 $ 45,800          
ASU 2016-18                
Organization And Summary Of Significant Policies [Line Items]                
Increase in net cash provided by investing activities           $ 500    
ASU 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606                
Organization And Summary Of Significant Policies [Line Items]                
Reduction to accumulated deficit 258,505              
Revenues   $ 32,558     $ 9,809      
ASU 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606 | Collaborative Arrangement with Ipsen | HCC Filing                
Organization And Summary Of Significant Policies [Line Items]                
Milestone payments earned $ 10,000              
Forecast | Collaborative Arrangement with Ipsen | EMA Approval - RCC | Licenses                
Organization And Summary Of Significant Policies [Line Items]                
Revenues             $ 40,000  
[1] The Condensed Consolidated Balance Sheet as of December 31, 2017 has been derived from the audited financial statements as of that date.